Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Taghi Manshouri

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

scientific article published on July 2005

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

scientific article published on 8 May 2006

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

scientific article published on January 2009

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

scientific article published on 29 September 2016

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

scientific article published in October 2002

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor

scientific article published on 21 April 2011

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations

scientific article published on 22 March 2018

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

scientific article published on 01 December 2003

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

scientific article published on 6 November 2009

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

scientific article

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

scientific article

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

scientific article

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

scientific article published on 15 August 2006

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

scientific article published on 23 June 2006

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

scientific article

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

scientific article

Imatinib effect on growth and signal transduction in polycythemia vera

scientific article published on June 2007

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status

scientific article published on 14 November 2008

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

scientific article

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome

scientific article published in May 2003

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

scientific article published in March 2003

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

scientific article

MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells

scientific article

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

scientific article published on 19 June 2013

Molecular differences between small and large cells in patients with chronic lymphocytic leukemia

scientific article

Myelofibrosis osteoclasts are clonal and functionally impaired

scientific article published on 11 February 2019

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

scientific article

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

scientific article published on 13 October 2009

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

scientific article published on June 2008

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

scientific article

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

scientific article published on 7 April 2010

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

scientific article

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

scientific article published on August 2016

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

scientific article

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

scientific article published on 19 June 2008

Therapy-related myelofibrosis does not appear to exist

scientific article published on 26 May 2017

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

scientific article

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2

scientific article published on 16 January 2020

Paulina is supported by:

About Paulina

Help